Literature DB >> 3605168

Cryptococcosis associated with low-dose methotrexate for arthritis.

M Altz-Smith, L G Kendall, A M Stamm.   

Abstract

One patient with psoriatic arthritis and a second with rheumatoid arthritis were each treated with low-dose methotrexate (10 to 15 mg per week, orally) for more than a year before pulmonary cryptococcosis developed. These are the first case reports of opportunistic fungal disease during this treatment. Low-dose methotrexate may be more immunosuppressive than has been appreciated. Patients demonstrating pneumonitis while receiving this therapy should be carefully evaluated to rule out an infectious cause.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3605168     DOI: 10.1016/0002-9343(87)90517-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Pulmonary coinfection by Pneumocystis carinii and Aspegillus fumigatus in a seronegative arthritis patient treated with low-dose methotrexate.

Authors:  M Mariñosa; A Soler; X Nogués; J Pedro-Botet
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

2.  Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis.

Authors:  J J Cornelissen; L J Bakker; M J Van der Veen; M Rozenberg-Arska; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

Review 3.  A risk-benefit assessment of methotrexate in corticosteroid-dependent asthma.

Authors:  T R Shulimzon; R J Shiner
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 4.  Corticosteroid sparing agents in asthma.

Authors:  J M Hill; A E Tattersfield
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 5.  Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent?

Authors:  S Tariq; S M Tariq
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

Review 6.  Methotrexate-related pulmonary complications in rheumatoid arthritis.

Authors:  P Barrera; R F Laan; P L van Riel; P N Dekhuijzen; A M Boerbooms; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

Review 7.  [Pneumocystis jiroveci pneumonia (PcP) in patients with rheumatic diseases: case report and review].

Authors:  B Bertisch; C Ruef
Journal:  Z Rheumatol       Date:  2006-02       Impact factor: 1.372

8.  Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate.

Authors:  M J van der Veen; A van der Heide; A A Kruize; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

Review 9.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 10.  Possible environmental exposure-associated pulmonary cryptococcosis in a patient with rheumatoid arthritis: a case report and literature review.

Authors:  Guangdie Yang; Junjun Chen; Jiani Ye; Yinan Yao; Zhijie Pan
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.